Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E29.42 EPS (ttm)1.11 Insider Own0.10% Shs Outstand6.19B Perf Week-1.68%
Market Cap202.35B Forward P/E13.00 EPS next Y2.52 Insider Trans0.00% Shs Float6.18B Perf Month10.36%
Income6.95B PEG5.63 EPS next Q0.55 Inst Own73.90% Short Float5.24% Perf Quarter8.36%
Sales48.85B P/S4.14 EPS this Y-21.50% Inst Trans0.09% Short Ratio6.64 Perf Half Y-6.05%
Book/sh10.48 P/B3.12 EPS next Y9.68% ROA5.70% Target Price37.90 Perf Year-0.25%
Cash/sh3.76 P/C8.69 EPS next 5Y5.23% ROE14.10% 52W Range27.96 - 35.53 Perf YTD2.35%
Dividend1.20 P/FCF42.56 EPS past 5Y1.60% ROI8.00% 52W High-7.94% Beta0.86
Dividend %3.67% Quick Ratio1.20 Sales past 5Y-5.60% Gross Margin80.40% 52W Low16.98% ATR0.53
Employees97900 Current Ratio1.50 Sales Q/Q7.10% Oper. Margin26.00% RSI (14)58.97 Volatility1.18% 1.84%
OptionableYes Debt/Eq0.60 EPS Q/Q-113.90% Profit Margin19.10% Rel Volume0.70 Prev Close32.91
ShortableYes LT Debt/Eq0.45 EarningsMay 03 BMO Payout92.70% Avg Volume48.77M Price32.71
Recom2.20 SMA200.76% SMA505.85% SMA2002.32% Volume34,203,634 Change-0.61%
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
Nov-27-12Downgrade MKM Partners Buy → Neutral $29 → $25
Oct-05-12Reiterated MKM Partners Buy $27 → $29
Apr-29-16 02:14PM  Business events scheduled for the coming month AP
12:53PM  What to Look For When Pfizer (PFE) Posts Q1 Results at TheStreet
12:30PM  AstraZeneca, Pfizer Said Among Firms Weighing Medivation Bid at Bloomberg
08:32AM  Pfizer Earnings Could Highlight Enbrel and Lyrica Sales Decline Yahoo Finance Contributors
08:14AM  Heavy put selling shows support for Pfizer optionMONSTER
Apr-28-16 03:12PM  How Did Eli Lilly Perform in 1Q16? Market Realist
01:52PM  Business events scheduled for the coming week AP
01:28PM  Shareholders criticize Pfizer after scrapped Allergan deal AP
12:06PM  Pfizer Who? Health-Care Deals Bounce Back From Inversion Scare at Bloomberg
12:00PM  Pfizer Hosts Annual Meeting of Shareholders Business Wire
08:39AM  Ohio Medicaid gets $25M from Pfizer drug discount settlement AP
06:16AM  Pfizer (PFE) to Report Q1 Earnings: Will the Stock Surprise? Zacks
Apr-27-16 05:17PM  Advocates hold NYC protest over price of pneumonia vaccine AP
04:24PM  Is Allergan On The Prowl For New Deals? at Forbes
03:45PM  Pfizer finalizes $785M settlement to resolve allegations of underpaying Medicaid rebates at American City Business Journals
03:29PM  Feds finalize $98M payment to whistleblowers in Pfizer Medicaid case at American City Business Journals
02:03PM  Pfizer agrees to $785M settlement in drug discount case AP
12:01PM  Pfizer to Pay $784.6 Million to Resolve Drug Discount Case at Bloomberg
10:49AM  Pfizer to pay $784.6 million to resolve Wyeth false claims lawsuit Reuters
09:15AM  Major Pharma Short Interest Remains Mixed, With 1 Massive Drop at 24/7 Wall St.
06:20AM  The 5 Most Shorted NYSE Stocks: Short Sellers Circle the Wagons at 24/7 Wall St.
Apr-26-16 11:25AM  Treasury Department Was 'Targeting' Pfizer-Allergan Deal at TheStreet
11:24AM  With New Treasury Department Rules, Is This the End of Tax Inversion Deals? at TheStreet
11:23AM  Tax Inversions: Explaining What They Are, How We Got Here and What's Next at TheStreet
08:30AM  Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled Business Wire
06:57AM  The Worlds 15 Top Selling Drugs at 24/7 Wall St.
12:48AM  [$$] Sheltering Foreign Profits From U.S. Taxes Is No Big Feat at The Wall Street Journal
Apr-25-16 01:31PM  Is Now the Time to Jump on Allergan? at TheStreet
10:58AM  Healthcare Q1 Earnings Look Solid: ETFs to Benefit Zacks
05:15AM  Management and Strategies Count Most Yahoo Finance Contributors
Apr-24-16 07:13PM  [$$] Vaccines are among big pharma's best-selling products at Financial Times
Apr-22-16 06:50PM  Study: No suicide risk for anti-smoking pills Chantix, Zyban AP
06:30PM  CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet Business Wire
02:00PM  Allergan bags a Boston-based eye bag cream developer for $85M at American City Business Journals
09:39AM  3 Stocks We're Ready to Buy Again at Motley Fool
08:35AM  What Weak Earnings At Goldman Sachs And J.P. Morgan Mean For Biotech at Forbes
Apr-21-16 02:00PM  Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders Business Wire
08:58AM  Better Buy: Pfizer Inc. vs. AbbVie at Motley Fool
Apr-19-16 03:07PM  Johnson & Johnson Boosts Guidance on Strong 1st-Quarter Results at Motley Fool
11:35AM  Another Duchenne-focused biotech joins the Boston area biotech hub at
10:14AM  Pfizer Reveals Positive Results Of Phase 3 PALOMA-2 Clinical Trial Of IBRANCE
08:00AM  Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib) Business Wire
Apr-18-16 12:30PM  2 Potential Targets of Allergan's Cash Influx
11:07AM  Could Xtandis Use for Breast Cancer Be a Valuation Driver?
01:00AM  Deal Scrapheap Starts to Fill Up As Mega-Mergers Fall Apart at Bloomberg
12:13AM  [$$] Lew Cant Change Law, So He Changes Rules at The Wall Street Journal
Apr-17-16 06:00PM  [$$] Lew Can't Change Law, So He Changes Rules at The Wall Street Journal
05:17PM  Loxo Cancer Drug Targets Gene Mutation With Durable Responses in Early Study at TheStreet
09:00AM  Jim Cramer: Pfizer Maintains Strong Growth Profile After Allergan Bust at TheStreet
Apr-16-16 09:36AM  Valeant vs. Abbott Labs: Which Is Better for My Portfolio? (VRX, ABT) at Investopedia
Apr-15-16 11:22AM  [$$] Best Bets in Biopharma at
09:08AM  Citigroup beats low expectations
08:24AM  15 Reasons to Buy Pfizer and Never Sell at Motley Fool
06:00AM  On the Latest BizWireTV Cars Get Night Vision and Healthy Eating Made More Accessible Business Wire
Apr-14-16 08:29PM  Ohio gov. wants NYers to get in Kasich state of mind at CNBC
07:05PM  Why Is Medivation at a Premium on an EV-to-EBITDA Basis?
01:04PM  What Analysts Expect from Pfizer in the Years to Come
11:37AM  Larry Summers: The prospect of Donald Trump being president is the gravest threat to America
10:47AM  Investors find safety in J&J shares, but run could stall
10:39AM  Spending On Drugs Will Drop As Top Sellers Go Generic at Forbes
09:12AM  Lew: Rules to block mergers were not retroactive at CNBC
06:00AM  FKINX: Top 5 Holdings Analysis (FKINX, RDS-A) at Investopedia
05:22AM  Politics is killing health-care stocks at MarketWatch
12:01AM  How corporate tax avoidance is hurting America and the rest of the world at MarketWatch
12:01AM  U.S. prescription drug spending to hit $400 bln a year by 2020 -IMS Reuters
Apr-13-16 02:53PM  Jim Cramer: What's Going on With Valeant, Allergan? at TheStreet
01:55PM  CIO Voices: Allergan's Sean Lennon Says Never Presume Job Security in a Merger at The Wall Street Journal
01:25PM  Jim Cramer: Pfizer Acting Better Since Broken Allergan Deal at TheStreet
12:15PM  Valeant Stock Flatlines Despite Trio Of Terrible News Events at Forbes
11:48AM  Analysts divided on Clovis stock after drug approval is delayed at MarketWatch
08:20AM  Top Jefferies Value Stocks to Buy Also Pay Big Dividends at 24/7 Wall St.
08:20AM  Cure Baldness? Heal Arthritis? Erase Wrinkles? An Unknown Billionaire's Quest To Reverse Aging at Forbes
Apr-12-16 05:42PM  Peering Into Allergan's Post-Pfizer Future at Motley Fool
02:36PM  11 Stocks Hurt By Treasury's New Tax Rules at
12:21PM  Pfizer Inc's Unspoken Message To Investors: It Was Always About Taxes at Motley Fool
12:05PM  Goldman Sachs: No Lessons Learned; People Must Be Held Accountable at TheStreet
12:03PM  Fair Share Or Not? Here's What America's 25 Most Profitable Companies Pay In Taxes at Forbes
12:00PM  Why Chinese Parents Are Shopping for Vaccines in Hong Kong at Bloomberg
11:26AM  Lawsuit vs Pfizer over Celebrex, Bextra safety is revived Reuters
10:38AM  Could Republican Plans to Lower the Corporate Tax Rate Bring Trillions Back to the U.S.? at TheStreet
09:50AM  Short Sellers Become More Selective in Major Pharma at 24/7 Wall St.
08:02AM  These 3 Demographic Factors Pretty Much Predetermine Your Financial Future
07:25AM  Unpredictable Precedent: Bread, Circuses And The Termination of Pfizer-Allergan at Forbes
06:50AM  The 5 Most Shorted NYSE Stocks: Big Changes to End the Quarter at 24/7 Wall St.
Apr-11-16 07:02PM  Johnson Controls-Tyco Will Sail By New Treasury Rules at The Wall Street Journal
06:04PM  Allergan's Share Price Makes No Sense -- Until You Consider These Two Things at Motley Fool
03:59PM  How Pfizer and Allergan's Merger Got Busted By Washington at Motley Fool
03:42PM  Anti-Inversion Proposal Has Far-Reaching Consequences: Davis Polk at The Wall Street Journal
01:53PM  General Electric's Secret Pharma Fail-Safe at Motley Fool
01:35PM  This Is the Easiest Way the U.S. Can Stop Corporate Tax Dodgers at Fortune
10:40AM  Paratek presents new trial data for antibiotic as late-stage trials continue at
10:07AM  Consumer Healthcare Should Be a Key Driver of Perrigos 2016 Growth
10:01AM  3 Ways Pfizer Can Improve Shareholder Value Without Allergan at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Allergan, Boeing, General Electric and International Business Machines
08:04AM  Drug stocks get shot in arm from busted deal at USA TODAY
08:02AM  The US Must Cut the Corporate Tax Rate to 15%
05:14AM  Politicians Impede Prosperity
05:00AM  Beyond Foiling Pfizer, U.S Aims at Intra-Company Loans `Fiction'
Apr-10-16 12:35PM  Analysts Making Major Changes on Top Dow Jones Industrial Stocks at 24/7 Wall St.
12:29PM  Have Billionaires Made the Right Call Betting on These Stocks? at Insider Monkey
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has strategic collaboration with KineMed Inc.; collaborations with BIND Therapeutics, Inc., Merck KGaA, and Syndax Pharmaceuticals, Inc.; research collaboration with Schrdinger, Inc.; license and collaboration agreement with Servier; strategic drug discovery agreement with Heptares; and collaboration agreement with Portola Pharmaceuticals Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541274,756Feb 26 03:05 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 24Option Exercise18.9062,4531,180,362140,772Feb 26 03:05 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9018,984358,79889,467Feb 26 03:05 PM
READ IAN CChairman & CEOFeb 24Option Exercise18.90584,11211,039,7172,030,151Feb 26 03:05 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541263,151Feb 26 03:05 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9052,570993,573188,679Feb 26 03:05 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9034,171645,832210,943Feb 26 03:05 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90210,2803,974,292622,467Feb 26 03:05 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90210,2803,974,292577,902Feb 26 03:05 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9078,8551,490,360149,135Feb 26 03:05 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9019,188362,65366,048Feb 26 03:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9034,171645,832149,482Feb 26 03:05 PM
BOURLA ALBERTGroup PresidentFeb 24Option Exercise18.9030,666579,587144,675Feb 26 03:03 PM
BOURLA ALBERTGroup PresidentDec 15Option Exercise26.2030,000786,000140,560Dec 16 06:46 PM
YOUNG JOHN DGroup PresidentDec 14Option Exercise26.2031,500825,300163,999Dec 16 06:55 PM
PFIZER INC10% OwnerOct 06Buy7.00714,2854,999,9952,253,509Oct 07 05:42 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 30Sale35.6524,704880,646174,611Aug 03 07:24 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Option Exercise25.8726,000672,62096,113Jun 12 09:26 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Sale34.3926,000894,15570,113Jun 12 09:26 AM
HILL CHARLES HExecutive Vice PresidentMay 29Sale34.9242,8701,497,02069,357Jun 02 04:54 PM